Market capitalization | $1.64b |
Enterprise Value | $1.22b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 58.21 |
EV/Sales (TTM) EV/Sales | 4.10 |
P/S ratio (TTM) P/S ratio | 5.51 |
P/B ratio (TTM) P/B ratio | 4.37 |
Revenue growth (TTM) Revenue growth | 26.48% |
Revenue (TTM) Revenue | $297.79m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
17 Analysts have issued a Immunocore Holdings plc - ADR forecast:
17 Analysts have issued a Immunocore Holdings plc - ADR forecast:
Sep '24 |
+/-
%
|
||
Revenue | 298 298 |
26%
26%
|
|
Gross Profit | 295 295 |
30%
30%
|
|
EBITDA | -66 -66 |
40%
40%
|
EBIT (Operating Income) EBIT | -68 -68 |
27%
27%
|
Net Profit | -47 -47 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Head office | United Kingdom |
CEO | Bahija Jallal |
Employees | 497 |
Founded | 2021 |
Website | immunocore.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.